Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Oseltamivir Phosphate
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioavailability of Oseltamivir Phosphate 75 mg With Regards to Reference Product
Details : Oseltamivir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 19, 2021
Lead Product(s) : Oseltamivir Phosphate
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vidofludimus Calcium,Oseltamivir Phosphate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : European Investment Bank
Deal Size : $28.6 million
Deal Type : Funding
Details : The venture loan is intended to support Immunic’s ongoing phase 2 CALVID-1 trial of its lead asset, IMU-838, in patients with moderate coronavirus disease 2019 (COVID-19).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 20, 2020
Lead Product(s) : Vidofludimus Calcium,Oseltamivir Phosphate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : European Investment Bank
Deal Size : $28.6 million
Deal Type : Funding
Lead Product(s) : Oseltamivir Phosphate
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Oseltamivir Phosphate and TAMIFLU Under Fed Condition in Healthy Volunteers
Details : Oseltamivir Phosphate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 02, 2020
Lead Product(s) : Oseltamivir Phosphate
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vidofludimus Calcium,Oseltamivir Phosphate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The IONIC trial is a prospective, randomized, parallel-group, open-label phase 2b study, designed to evaluate efficacy & safety of IMU-838 in combination with the neuraminidase inhibitor, Oseltamivir, in approximately 120 adult COVID-19 patients.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 27, 2020
Lead Product(s) : Vidofludimus Calcium,Oseltamivir Phosphate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oseltamivir Phosphate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Oseltamivir Versus Paracetamol for Influenza-like Illness During the Influenza Season
Details : Oseltamivir is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Influenza, Human.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 27, 2018
Lead Product(s) : Oseltamivir Phosphate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oseltamivir Phosphate
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Li Ka Shing Knowledge Institute | University of Toronto
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Oseltamivir is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Purpura, Thrombocytopenic, Idiopathic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 09, 2018
Lead Product(s) : Oseltamivir Phosphate
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Li Ka Shing Knowledge Institute | University of Toronto
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oseltamivir Phosphate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Oseltamivir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Influenza, Human.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 23, 2017
Lead Product(s) : Oseltamivir Phosphate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oseltamivir Phosphate
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Oseltamivir is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 23, 2016
Lead Product(s) : Oseltamivir Phosphate
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oseltamivir Phosphate
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Oseltamivir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 24, 2016
Lead Product(s) : Oseltamivir Phosphate
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oseltamivir Phosphate
Therapeutic Area : Nephrology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Oseltamivir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Kidney Failure, Chronic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 01, 2015
Lead Product(s) : Oseltamivir Phosphate
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable